Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease

Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease

US Patent 10787669 · Granted Sep 29, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antisense compounds targeting genes associated with cystic fibrosis2024
Compounds and methods for the modulation of amyloid-β precursor protein2023
Antisense compounds targeting genes associated with cystic fibrosis2021
Glucocerebrosidase gene therapy for Parkinson's disease2021
Antisense compounds targeting genes associated with cystic fibrosis2020
Antisense compounds targeting genes associated with cystic fibrosis2020
Antisense compounds targeting apolipoprotein E receptor 22019
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treat2019
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treat2019
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treat2019
Dopaminergic neurons differentiated from pluripotent stem cells and uses thereof2018
Antisense compounds targeting genes associated with cystic fibrosis2017